Eli Lilly and Co. announced Monday that the FDA has cleared the use of the antidepressant Cymbalta to treat fibromyalgia, a chronic illness characterized by extensive body pain, tenderness and fatigue. The expanded approval puts Cymbalta in competition with Pfizer's Lyrica, the first fibromyalgia medication to win FDA approval.

Related Summaries